Omnicell, Inc.

NMS: OMCL
Live Quote

📈 ZcoreAI Score

Our AI model analyzes Omnicell, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.

Get OMCL Z-Score →

About Omnicell, Inc.

Healthcare Health Information Services
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.

📊 Fundamental Analysis

Omnicell, Inc. demonstrates a profit margin of 0.2%, which is below the sector average, suggesting competitive pressure.

The company recently reported 2.3% revenue growth, which is modest compared to its industry peers.

Return on Equity (ROE) is 0.2%, which suggests room for improvement in capital utilization.

At a current price of $34.40, OMCL currently sits at the 36th percentile of its 52-week range (Range: $22.66 - $55.00).

💰 Valuation Insight

OMCL trades at a 3340.0% premium to the sector average PE of 25.00. Analysts expect earnings growth, as indicated by a lower forward PE.

🏥 Financial Health

🔴 Profit Margin Weak
Debt/Equity Excellent
🔴 Revenue Growth Weak
🔴 Return on Equity Weak
⚠️ Beta (Risk) Moderate Volatility

Key Financials

Market Cap
$1.56B
Trailing P/E
860.00
Forward P/E
16.48
Beta (5Y)
0.86
52W High
$55.00
52W Low
$22.66
Avg Volume
645K
Day High
Day Low
Get OMCL Z-Score on Dashboard 🚀